Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Enhanced Ocular Anti-Inflammatory Activity Of Ibuprofen Carried By An Eudragit RS100® Nanoparticle Suspension

C. Bucolo, A. Maltese, G. Puglisi, R. Pignatello
Published 2002 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: To investigate the ocular pharmacodynamic profile of a polymer nanoparticle system loaded with sodium ibuprofen (IBU-RS) in comparison to an aqueous solution of ibuprofen lysinate (IBL) in the rabbit eye both being applied topically. Methods: Ocular inflammation was elicited by topical application of sodium arachidonate. Inflammation was quantified according to a modified Draize test. The protein level and the number of polymorphonuclear leukocytes in the aqueous humor were assessed after 2 h from arachidonate instillation. The ibuprofen concentration in the aqueous humor was evaluated by HPLC assay. The physico-chemical properties of nanoparticles were also evaluated. Results: The IBU-RS nanosuspension formulation significantly reduced the primary signs of ocular inflammation as well as significantly reducing the protein level and the number of polymorphonuclear leukocytes in the aqueous humor compared with the IBL formulation. Furthermore, the aqueous humor drug concentration from the group treated with IBU-RS was significantly higher compared to the IBL-treated group. The IBU-RS nanosuspensions showed very interesting size and surface charge values, adequate for ophthalmic administration. Conclusions: The pharmacological profile of the topical IBU-RS nanosuspension formulation described in this study indicates that the dispersion of the drug within RS polymer nanoparticles increased its ocular bioavailability and ultimately its pharmacological activity.
This paper references
10.1016/S1350-9462(97)00002-5
Ophthalmic drug delivery systems—Recent advances
C. L. Bourlais (1998)
10.1023/A:1018936205485
Poly(ε-Caprolactone) Nanocapsules in Carteolol Ophthalmic Delivery
L. Marchal-Heussler (2004)
10.1089/JOP.1991.7.125
Effects of sodium naproxen eye drops on rabbit ocular inflammation induced by sodium arachidonate.
S. Spampinato (1991)
10.1016/S0142-9612(02)00080-7
Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.
R. Pignatello (2002)
10.1002/JPS.2600780118
Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method.
Y. Kawashima (1989)
Ocular pharmacokinetics; in Sears ML (ed): Pharmacology of the Eye
DM Maurice (1984)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
Shedduck JA: Eye irritation; in Marzulli FM, Maibach HI (ed): Advances in Modern Toxicology
TO McDonald (1977)
10.1016/0168-3659(94)90225-9
Evaluation of pilocarpine-loaded albumin particles as drug delivery systems for controlled delivery in the eye. I: In vitro and in vivo characterisation
A. Zimmer (1994)
10.3109/02652048609031575
Ocular drug delivery of progesterone using nanoparticles.
V. Li (1986)
10.1016/0378-5173(86)90053-0
Enhancement of the myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate nanoparticles
T. Harmia (1986)
Contr Rel 1994;32:57–70
P Calvo (1994)
10.1111/j.2042-7158.1991.tb03534.x
Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles
C. Losa (1991)
10.1016/S0378-5173(97)00083-5
Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers
P. Calvo (1997)



This paper is referenced by
10.1007/s13204-018-0850-5
Tolnaftate–graphene composite-loaded nanoengineered electrospun scaffolds as efficient therapeutic dressing material for regimen of dermatomycosis
S. Misra (2018)
Development and characterization of new dosage forms based on drug containing aqueous colloidal polymer dispersion
C. Loira-Pastoriza (2013)
10.3109/9781420045154-21
Toxicity of nanoparticles in the eye
T. W. Prow (2007)
DESIGN, DEVELOPMENT AND EVALUATION OF NANOSUSPENSIONS FOR ENHANCEMENT OF ORAL BIOAVAILABILITY OF POORLY SOLUBLE DRUGS
PH.D. SYNOPSIS (2018)
10.1016/j.ijpharm.2010.07.044
Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives.
R. Shegokar (2010)
10.1016/j.colsurfb.2016.04.054
PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization.
E. Sánchez-López (2016)
10.1007/978-1-4419-1087-5_5
Preclinical Development for Suspensions
S. Garad (2010)
Evaluation of the parameters of a bead milling process to produce a non-aqueous nanosuspension
C. J. Ribeiro (2017)
10.1007/s11095-006-0284-8
Nanotechnology: Intelligent Design to Treat Complex Disease
P. Couvreur (2006)
10.1007/978-3-319-29346-2
Nano-Biomaterials For Ophthalmic Drug Delivery
Y. Pathak (2016)
10.1002/wnan.65
Toxicity of nanomaterials to the eye.
T. Prow (2010)
10.2147/IJN.S66300
Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
Amanda CM Saúde (2014)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.4018/978-1-4666-6304-6.CH009
Nanosuspensions in Nanobiomedicine
M. Lakshmipathy (2015)
10.1002/9781118444726.CH8
Novel Top‐Down Technologies: Effective Production of Ultra‐Fine Drug Nanocrystals
C. Keck (2013)
10.1016/j.ijpharm.2020.119133
Nanocomplexes based polyvinylpyrrolidone K-17PF for ocular drug delivery of naringenin.
H. Wang (2020)
10.1016/j.ijpharm.2017.07.065
Non-invasive strategies for targeting the posterior segment of eye.
Asadullah Madni (2017)
10.1002/9780470571224.PSE358
Ocular Drug Delivery
I. Rupenthal (2010)
10.1080/10717544.2019.1568624
Ultra-small micelles based on polyoxyl 15 hydroxystearate for ocular delivery of myricetin: optimization, in vitro, and in vivo evaluation
Yuzhen Hou (2019)
10.18433/J3SW2T
Preparation and Physicochemical Characterization of Eudragit ® RL100 Nanosuspension with potential for Ocular Delivery of Sulfacetamide
B. Mandal (2010)
10.3390/pharmaceutics12060570
Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation
R. Mazet (2020)
10.1016/S1773-2247(07)50007-9
Evaluation of the physicochemical characteristics and activity of various kinds of ciprofloxacin HCl-loaded cationic nanoparticles
K. Dillen (2007)
Development and evaluation of moxifloxacin hydrochloride loaded microspheres for controlled release ophthalmic delivery
Sb Khairnar (2016)
10.1016/J.ADDR.2005.07.005
The use of mucoadhesive polymers in ocular drug delivery.
A. Ludwig (2005)
10.1080/03639045.2017.1349787
New nanomicelle curcumin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment
Mengshuang Li (2017)
10.17169/REFUBIUM-27720
Herstellung und Charakterisierung nanodisperser Arzneiformen in wässrigen und nichtwässrigen Medien und Kontrolle der Freisetzung
Ansgar Brinkmann (2020)
10.1016/J.YRTPH.2006.04.009
Nanomedicine: An unresolved regulatory issue.
V. W. Chan (2006)
10.1016/j.ijpharm.2020.119035
Novel ultrasmall nanomicelles based on rebaudioside A: A potential nanoplatform for the ocular delivery of pterostilbene.
Kaichao Song (2020)
10.1016/j.nano.2009.02.003
Nanomedicines for ocular NSAIDs: safety on drug delivery.
J. Araújo (2009)
10.1016/j.msec.2016.10.017
A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: In vitro, in vivo and stability studies.
Lalaji V Rathod (2017)
Nanotechnolgy a Novel Ocular Drug Delivery : A Review
C. Kaur (2017)
10.3390/nano10040720
Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study
E. Sánchez-López (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar